ClinicalTrials.gg
RecruitingNCT06583083SPIRIT-02Updated Apr 14, 2026

Sintilimab With P-GEMOX Versus the P-GEMOX in the Teatment of Advanced-stage Extranodal Natural Killer/T Cell Lymphoma

A Phase 2 interventional study of Sintilimab with P-GEMOX Regimen and P-GEMOX Regimen in Natural Killer/T-Cell Lymphoma, Nasal and Nasal-Type, sponsored by Sun Yat-sen University. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-14.

Sponsored by Sun Yat-sen University · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Oct 2024; still recruiting 2 years 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
84
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 11 studies in Lymphoma, T-Cell by Sun Yat-sen University — 6 open to participants now, 8 under way, 1 of them phase 3. Lymphoma, T-Cell · Sun Yat-sen University.

Started
2024
with 1 other
Phase 2
4 of 11
2 open now
Registered
7th of 11
by date

Among the 11 studies in Lymphoma, T-Cell by Sun Yat-sen University, this one is one of 2 that started in 2024, is one of 4 in phase 2, and was the 7th registered.

Lymphoma, T-Cell

310 studies on the registry are indexed under Lymphoma, T-Cell; 76 are open to participants now.

Browse Lymphoma, T-Cell studies →

Open to participants now

6 of the 11 studies in Lymphoma, T-Cell by Sun Yat-sen University are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

Where they have run

Who these studies take

Of the 66 Lymphoma, T-Cell studies recruiting now, 40 (61%) set no upper age limit and 20 (30%) stop at 75 or younger; 14 take children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Lymphoma, T-Cell by Sun Yat-sen University, or all of them as a file.
02

Study summary

Extranodal NK/T-cell lymphoma is a rare and highly aggressive subtype of non-Hodgkin lymphoma. While the overall survival rates have improved for early-stage ENKTL patients, the prognosis for those with advanced disease remains poor, and there is currently no standard treatment. PD-1/PD-L1 inhibitors have demonstrated significant efficacy in various cancers, and recent studies have shown promising results in extranodal NK/T-cell lymphoma as well. Although PD-1 antibodies have exhibited efficacy in relapsed or refractory patients, their effectiveness when combined with chemotherapy as a first-line treatment remains unclear. This study aims to evaluate the efficacy and safety of sintilimab combined with chemotherapy in a randomized controlled trial for newly diagnosed advanced extranodal NK/T-cell lymphoma patients, while also exploring potential biomarkers that may predict treatment outcomes, offering new therapeutic options for extranodal NK/T-cell lymphoma patients.

03

Conditions studied

  • Natural Killer/T-Cell Lymphoma, Nasal and Nasal-Type

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. diagnosed with ENKTL.
  2. Advanced stage.
  3. Has at least one measurable or assessable lesion.
  4. Age > 18 years, no gender restrictions, with an expected survival of more than 3 months.
  5. Willing to participate in the clinical study; fully informed and has signed a written form.
  6. Adequate organ and bone marrow function.

Exclusion criteria

Exclusion Criteria:

  1. Aggressive NK-cell leukemia.
  2. Central nervous system involvement.
  3. Patients with significant dysfunction of vital organs.
  4. History of allergy to the drug, similar drugs, or .
  5. Less than 6 weeks since major organ surgery (excluding surgery for purposes).
  6. Pregnant or breastfeeding women, and women of who are unwilling to use .
  7. Active infection, excluding fever related to tumor-associated B symptoms.
  8. Known history of (HIV) infection and/or acquired immunodeficiency syndrome (AIDS).
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
84 participants (estimated)

Study arms

  • Experimental
    experimental group

    Sintilimab with P-GEMOX Regimen

    Drug: Sintilimab with P-GEMOX Regimen

  • Active comparator
    control group

    P-GEMOX Regimen

    Drug: P-GEMOX Regimen

Interventions

  • DrugSintilimab with P-GEMOX Regimen

    Drug page: SintilimabStudies of SintilimabSintilimab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Sintilimab intravenous drip, Pegaspargase intramuscular injection, gemcitabine intravenous drip, oxaliplatin intravenous drip

    Also known as: Sintilimab, Pegaspargase, gemcitabine, oxaliplatin

  • DrugP-GEMOX Regimen

    Pegaspargase intramuscular injection, gemcitabine intravenous drip, oxaliplatin intravenous drip

    Also known as: Pegaspargase, gemcitabine, oxaliplatin

06

What researchers measure

Primary outcomes

  1. PFS

    progression free survival

    Time frame: Up to 4 years

Secondary outcomes

  1. ORR rate

    objective response rate

    Time frame: Up to 4 years

  2. CR rate

    complete response rate

    Time frame: Up to 4 years

  3. OS

    overall survival

    Time frame: Up to 4 years

  4. Adverse events

    The incedence of all adverse events (AEs), serious adverse events (SAEs) and treatment-related adverse events (TEAEs)

    Time frame: Up to 4 years

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2024 (actual). Primary completion is estimated for Aug 2026, 22 months after the start.

Of 56 non-industry phase 2 interventional studies under Lymphoma, T-Cell, half reached primary completion within 68 months of starting (the median), counting those still running; a quarter within 33 and three quarters within 110. This study's planned 22 months is below that.

Counting every sponsor, half of 66 studies reached it within 68 months; a quarter within 33 and three quarters within 99.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 28, 2024
First posted
Sep 3, 2024
StartActual
Oct 22, 2024
Primary completionEst.
Aug 28, 2026
CompletionEst.
Aug 28, 2026
Last update
Apr 14, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 14, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06583083
Responsible party
Qingqing Cai (Professor, Sun Yat-sen University) — Principal investigator
First posted
Sep 3, 2024
Start date
Oct 22, 2024
Primary completion
Aug 28, 2026 (estimated)
Completion
Aug 28, 2026 (estimated)
Last update
Apr 14, 2026

Study contacts

Cai Qingqing, MD.PhD
Contact
caiqq@sysucc.org.cn
(020)87342823

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sintilimab

Start the discussion